The FDA Comment Period Closed June 29. What Happens Next for Compounded GLP-1s?

On June 29, 2026, the public comment period closed on the FDA's proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. This is the regulatory mechanism that would permanently bar outsourcing facilities from compounding these medications — regardless of future shortages.

Here's what happens next, what the comments likely said, and what this means for patients currently using compounded GLP-1 medications.

The Regulatory Timeline

Administrative rulemaking follows a predictable sequence. Here's where we are and what's ahead:

What the Comments Likely Argued

The FDA is legally required to review and respond to all substantive public comments before finalizing the rule. Based on the organizations that signaled intent to file:

Alliance for Pharmacy Compounding (APC) likely argued that patient access will be harmed, particularly for Medicare beneficiaries not eligible for the Bridge program and uninsured patients for whom compounded medications are the only affordable option. They've consistently maintained that 503B facilities fill a legitimate clinical need.

National Community Pharmacists Association (NCPA) likely emphasized the role of community pharmacies and the difference between legitimate compounding and mass production intended to circumvent the approval process.

Novo Nordisk and Eli Lilly almost certainly filed comments supporting the exclusion, citing safety concerns (455+ adverse event reports for compounded semaglutide, 320+ for compounded tirzepatide) and their expanded access programs (TrumpRx, savings cards, Medicare Bridge).

Individual patients filed what are likely thousands of comments describing how compounded GLP-1s were the only medications they could afford, and how restriction would force them to stop treatment entirely.

What "Finalization" Means in Practice

If the rule is finalized as proposed, 503B outsourcing facilities would be permanently prohibited from compounding semaglutide, tirzepatide, or liraglutide from bulk active pharmaceutical ingredients. This applies regardless of any future shortage designation — it's a permanent exclusion.

The practical impact is significant. 503B facilities were the primary source of the low-cost compounded GLP-1 medications that powered the telehealth boom in 2023–2025. Without them, the remaining supply comes from 503A pharmacies — which operate at smaller scale, require individual prescriptions, and cannot produce medications in bulk for distribution to clinics.

What This Means for Patients Right Now

Nothing changes immediately. The comment period closing doesn't trigger any new enforcement. The FDA must review comments, potentially revise the proposal, and publish a final rule before any prohibition takes effect. That process typically takes 6–12 months.

In the interim, 503A pharmacies continue to operate legally. If your compounding pharmacy is a state-licensed 503A facility compounding patient-specific prescriptions, your access is not affected by this rulemaking. Verify your pharmacy's status with your state board of pharmacy.